Traditional thinking has viewed atherosclerosis as “inexorably progressive,” say researchers who offer a more optimistic outlook: that aggressive treatment can actually reverse the atherosclerotic disease process.
They conducted a multinational study of very high-intensity rosuvastatin calcium (Crestor canadian, AstraZeneca) at a dose of 40 mg/day in 349 patients at 53 community and tertiary-care centers.
The treatment halved low-density lipo-protein (LDL)-cholesterol levels, from a mean of 130.4 to 60.8 mg/dl. Mean high-density lipoprotein (HDL) cholesterol increased 14.7%, from 43.1 mg/dl at the baseline evaluation to 49 mg/dl. The total atheroma volume declined by a median of 6.8%. The average change in the percentage of atheroma volume in the most diseased subsegment was -6.1 mm3.
Generic Rosuvastatin 40 mg/day was well tolerated, with no cases of rhabdomyolysis.